Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names


Shareholder links

Our website ranking of DVL: rating 5
(5 out of 5)



Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000DVL0
Address: c/o Pitcher Partners, Level 13, 664 Collins Street, Docklands, Victoria, 3008
Tel:  1800 367 728Fax: +61-(0)3-8610-1024

Date first listed: 11/12/2013
Company Secretary: Justin Mouchacca
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Medical research and development, supplying medical, sporting and occupational health and safety products, devices and services

News & Events

Expand this box to read and print

The suspension of trading in the securities of dorsaVi Ltd will be lifted immediately, following the release by DVL of an announcement regarding a review of its operations and the raising of additional capital.


A decision has been taken to further reduce cash expenses through both operational and staff related changes. The changes made in March 2019, and these new changes, have led to a reduction of 25% FTE equivalent headcount. There has also been a reduction in the salary of the CEO, Andrew Ronchi, in line with his original Australian based salary. The company's current cash and cash equivalents is now $1.66m. Total estimated cash outflows for this quarter remain at $1.58m of which $1.04m has already been paid. Cash receipts from operations for the current quarter are estimated to be approximately $0.6m of which $0.5m has been received. Whilst the operational changes will reduce the company's expenditure, the board has also resolved to raise further capital during the current quarter subject to market conditions. If a capital raising is unsuccessful the company will explore alternative options to achieve a cash flow neutral position.


The securities of dorsaVi Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of DVL, pending the release of an announcement regarding the raising of additional capital.


listed entity carried for record purposes only



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    08/09/2021Andrew Ronchi205,000$0.024$4,920
    21/12/2018Andrew Ronchi3,200$0.058$186

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Aaron ChanCFO18/09/2023
    Caroline ElliottIndependent Director24/11/2017
    Michael WinloNon Exec Director25/10/2023
    Michael PanaccioNon Exec Director18/05/2008
    Ashraf AttiaNon Exec Director16/07/2008
    Andrew RonchiDirector20/02/2008

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Troy Di DomenicoCFO04/10/202118/09/2023
    Gregory TweedlyChairman31/10/201326/11/2021
    Damian ConnellanCFO04/10/2021
    Herb ElliottNon Exec Chairman, Independent Director29/10/201323/11/2017
    Jerome WhelanCFO07/05/201412/10/2015

    Date of first appointment, title may have changed.